What to expect when Cochlear (ASX:COH) releases its half year results

What should you expect from Cochlear?

| More on:
Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Cochlear is releasing its half year results next week
  • The hearings solutions company has provided not first half guidance but is expecting full year profit growth of 12% to 20% 
  • The market consensus is for modest first half profit growth

The Cochlear Limited (ASX: COH) share price will be one to watch next week.

On 22 February, the hearing solutions company is scheduled to release its half year results.

Ahead of the release, let's take a look to see what the market is expecting from Cochlear.

What should you expect from Cochlear?

The market is expecting a mildly positive half year result from Cochlear next week. According to a note out of Citi, the market consensus estimate is for a net profit of $127.6 million.

This is up marginally on the prior corresponding period when the company reported a net profit of $125.3 million.

However, Citi is expecting Cochlear to outperform the market's expectations. It is forecasting a first half net profit of $140.9 million, representing growth of 12.5% over the prior corresponding period.

If Cochlear were to achieve Citi's estimate, it would mean it is on course to deliver on its guidance in FY 2022. At its annual general meeting, management reaffirmed its FY 2022 guidance for underlying net profit growth of between 12% and 20%.

Management advised that this is expected to be underpinned by market growth, with a continuing recovery in surgery rates across many countries more affected by COVID.

What are others saying?

While it hasn't provided a first half estimate, the team at Goldman Sachs expects a full year result in August ahead of guidance.

It commented: "We forecast $288m NPAT (17.7% margin) in FY22, which remains above COH guidance of $265-285m."

Though, the broker has warned that while COVID headwinds are easing, "it is possible there is some persistent hesitancy amongst a proportion of its target market in DMs (aged 70+)." Therefore, investors may want to listen out for any commentary on that front.

All in all, the result could be one of the more interesting ones this season.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »